Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications

Jaspreet Kaur Boparai¹ and Pushpender Kumar Sharma¹,*

¹Department of Biotechnology, Sri Guru Granth Sahib World University, Fatehgarh Sahib, Punjab, India

Abstract: Antimicrobial peptides in recent years have gained increased interest among scientists, health professionals and the pharmaceutical companies owing to their therapeutic potential. These are low molecular weight proteins with broad range antimicrobial and immuno modulatory activities against infectious bacteria (Gram positive and Gram negative), viruses and fungi. Inability of micro-organisms to develop resistance against most of the antimicrobial peptide has made them as an efficient product which can greatly impact the new era of antimicrobials. In addition to this these peptides also demonstrates increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking properties. Pharmaceutical industries are therefore conducting appropriate clinical trials to develop these peptides as potential therapeutic drugs. More than 60 peptide drugs have already reached the market and several hundreds of novel therapeutic peptides are in preclinical and clinical development. Rational designing can be used further to modify the chemical and physical properties of existing peptides. This mini review will discuss the sources, mechanism and recent therapeutic applications of antimicrobial peptides in treatment of infectious diseases.

Keywords: Antimicrobial peptides, antibiotic resistance, therapeutic drugs, infectious diseases, clinical trials, immuno modulatory activities.

1. INTRODUCTION

Antimicrobial Peptides (AMPs) are low molecular weight proteins with broad spectrum antimicrobial and immuno modulatory activities against infectious bacteria (Gram positive and Gram negative), viruses and fungi [1]. These antimicrobial peptides have been classified according to their physiochemical properties like net charge, secondary structural contents and solubility [2]. AMPs contain both hydrophobic and hydrophilic side chain that enables these molecules to be soluble in aqueous environments [3]. Amongst the most abundant and widespread AMPs in nature, the cationic alpha-helical AMPs are able to perturb the bacterial cytoplasmic membrane causing cell death by osmotic shock. Some of the most important class of AMPs in these groups are cecropin, magainin, the human cathelicidin LL-37, their derivatives and proline rich Antimicrobial Peptides (prAMPs) [4-12]. Besides cationic AMPs, anionic AMPs have also been described [13]. One positive feature of AMPs is their low propensity towards developing resistance which may be attribute to its distinguished mode of action on the plasma membrane, where it natively folds into three dimensional amphiphilic structure that causes bacterial cell disruption, as documented in previous studies [14, 15]. These peptides initially interact with the bacterial cell envelope, and later translocates to cytosol [16, 17]. And unlike common antibiotics, AMPs do not inhibit peptidoglycan synthesis by binding with proteins; rather create pores in membrane forming complex with precursor molecule present in the membrane [18, 19]. Antimicrobial peptides are diverse group of proteins divided into many subgroups on the basis of their amino acid composition and structure and other properties [20, 21]. The secondary structures of these short peptide may have four architectures that include i) α-helical, ii) β-stranded due to the presence of 2 or more disulfide bonds, iii) β-hairpin or loop due to the presence of a single disulfide bond and/or cyclization of the peptide chain, and iv) extended [22]. AMPs participate in the innate immune response by providing rapid first line defence against infection [1]. This review will focus and report various sources of antimicrobial peptides, variety of structure, mechanisms of action and therapeutic interventions of antimicrobial peptides.

2. SOURCES OF AMPs

Discovery of AMPs dates back to 1939, when Dubos extracted an antimicrobial agent from a soil Bacillus strain. After that several AMPs have been discovered from both the prokaryotes and eukaryotes [23-25], frog skin alone is source of more than 300 different AMPs [24]. Recently, scientists from Japan have successfully explained the molecular
mechanism of antimicrobial peptides, Bombyxins H2 and H4 discovered from skin secretions of frog species *Bombina variegata*. Both these antimicrobial peptides have shown promising ability to inhibit highly infectious and fatal disease called Leishmaniasis. Mechanism of action of these peptides will enable us to better understand how defence system of the frog has evolved and how this can be implemented in developing antimicrobial peptides against important microbial infections. It was reported that Leishmania affect almost 20 million people worldwide and is the cause of approximately 30,000 deaths each year [26]. Other AMPs discovered are defensin from rabbit leukocytes [27], lectoferrin from cow milk [28], lysosomes of human leukocytes [29] and low molecular weight antimicrobial peptide from human female reproductive tract [30]. Several *Bacillus* strains producing antimicrobial peptides have been identified which have shown promising inhibitory activity against *Shigella*, *Salmonella*, *E. coli* and *Staphylococcus aureus* [31-34]. In another study, an antimicrobial peptide reported from *Bacillus* sp. [31, 32] found to be active against *Staphylococcus aureus*, *Atheromonas* sp. strain CCSH174 and *Klebsiella pneumoniae*. An extracellular antimicrobial peptide has also been discovered from *Propionibacterium jenseni* [35]. Antimicrobial peptides isolated from *Pseudomonas* [33] showed activity against *Shigella*, *Salmonella*, *E. coli*, *Staphylococcus aureus*. Another peptide which as shown high inhibitory activity against bovine film was discovered in year 2015 [36].

Researchers have also modified lactoferrin of bovine at the N-terminal domain that demonstrated high activity against multidrug-resistant bacteria and *Candida* [37]. Antimicrobial Peptide Database (APD) contains entry of ~2981 antimicrobial peptides from six kingdoms (335 bacteriocins/peptide antibiotics from bacteria, 4 from archaea, 8 from protists, 13 from fungi, 342 from plants, and 2200 from animals, including some synthetic peptides, in total, more than 5,000 AMPs have been discovered or synthesized till date [38]. More recently, glycocin, a small antimicrobial peptide was discovered from thermophilic bacterium which was found to be stable at relatively high temperatures, the gene encoding glycocin was successfully transformed in *E. coli* bacterium [39]. Table 1 further summarizes discovery of various AMPs from variety of organisms [40-88].

3. INSIGHTS INTO MECHANISM OF ACTION OF AMPs

Antimicrobial peptides interact with bacterial cell membrane through electrostatic interactions [89] thus making it difficult for bacteria to develop resistance unlike conventional antibiotics [90]. Based on their mode of action, these peptides are classified into membrane acting and non membrane acting peptides. Membrane acting peptides mainly harbour cationic peptides causing membrane disruptions, whereas non membrane peptides are capable of translocation across the membrane without damaging it as also reviewed in previous study [91]. Few antibacterial peptides create trans-membrane pores on the target membrane and include defensin [92], melittin [93], againins [94], and LL-37 [95]. Antimicrobial peptides such as buforin II [82], dermaseptin [96], HNP-1 [97], pleurocidin [98], indolicidin [99], pyrrocobin [100], and mersacidin [101] these peptides translocates across the cell membrane and disrupt normal cell functioning [102]. Outer membrane of prokaryotic cell is negatively charged owing to presence of lipopolysaccharides or teichoic acid, whereas the outer leaflet of eukaryotic cell consists of zwitterionic phosphatidylcholine and sphingomyelin phospholipids. Cationic AMPs interact with negatively charged outer microbial membranes *via* selective interactions [103], and attain well-defined secondary structures, makes cell permeable and finally disrupt bacterial membranes [15]. These peptides show dynamics in structure and topologies during their interactions with the microbial cell membranes [104, 105].

AMPs also hamper processes like protein synthesis, nucleic acid synthesis, enzymatic activities, and cell wall synthesis [106-108]. Several factors that include magnitude and charge of the outer membrane, concentration of negatively charged molecules, molecular architecture, and membrane fluidity are essential for the transportation of peptide across the membrane [109]. The membrane fluidity also regulates adsorption and insertion of AMPs into the cell membrane. Malanovic and Lohnerin in year (2016) studied antimicrobial peptides against Gram positive bacteria and found that prior targeting the cytoplasmic membrane these peptides cross the cell wall components such as lipoteichoic acids and peptidoglycan [110]. It was established that highly conserved precursors of cell wall components, especially lipid II are directly targeted by AMPs [111]. Majority of these antimicrobial peptides fold into amphipathic conformations while interacting with membrane [112]. Some of the antimicrobial peptides crosses lipid bilayer, target intracellular components, binds DNA, block enzyme activity, inhibit synthesis of proteins, cell wall, and nucleic acids [113, 114]. AMPs thus displays antibacterial efficacy because of intracellular inhibitory mechanisms. Unfortunately, these aspects remain elusive, various models used to explain the AMP mechanism of action on bacterial membrane are *Barrel-stave mechanism* [115] *Carpet model* [116] and *Toroidal pore model* [117] (Figure 1).

Despite all reported evidences, the mechanism of action and disruption of membranes is not fully understood. Some examples of antimicrobial peptides showing intracellular activities are reported in Table 2 [118-121].

4. APPLICATIONS OF AMPs

4.1. Application in Ophthalmology

AMPs are being employed in ophthalmology, a previous study reported use of rabbit alpha defensin (NP-1) against several ocular infections [122]. Recently, a cecropin analogue, Hecate has also shown inhibitory action against many *Acanthamoeba species in vitro*. Among other tested cecropin analogues SHIVA-11 is widely used against various ocular infections [123]. Table 3 further summarizes examples of peptides and their activity against relevant pathogens in ocular infections.

4.2. Treatment of Local Infections

Several peptides have been used in treating local infections, a peptide NEUPREX (rBPI21, opebacan) is
### Table 1. List of antimicrobial peptides from different sources.

| AMPs from Insects | Source | Amino Acid Number | Antimicrobial Activity | References |
|------------------|--------|-------------------|------------------------|------------|
| **S. No.** | **Peptide Name** | **Source** | **AMPs from Insects** | **Source** | **Amino Acid Number** | **Antimicrobial Activity** | **References** |
| 1 | Acaloleptin | *Acalolepta luxuriosa* | 71 | **G⁺, G⁻** | [40] |
| 2 | Andropin | *Drosophila melanogaster* | 34 | **G⁺** | [41] |
| 3 | Apidaecin IA | *Apis mellifera* | 18 | **G⁻** | [42] |
| 4 | Cecropin | *Hyalophora cecropia* | 37 | **G⁻** | [43] |
| 5 | Defensin-α | *Aedes aegypti* | 40 | **G⁺, G⁻** | [44] |
| 6 | Drosomycin | *Drosophila melanogaster* | 44 | **F** | [45] |
| 7 | Holotricin | *Holotrichia diomphalia* | 43 | **G⁺, G⁻** | [46] |
| 8 | Sapecin-α | *Sarcophaga peregrine* | 40 | **G⁺, G⁻** | [47] |
| 9 | Tenicin 1 | *Tenebrio molitor* | 43 | **G⁺, G⁻** | [48] |
| 10 | Thanatin | *Podisus maculiventris* | 21 | **G⁺, G⁻** | [49] |

| From Humans | **Source** | **Amino Acid Number** | **Antimicrobial Activity** | **References** |
|-------------|-----------|-----------------------|-----------------------------|------------|
| 1 | Cathelicidins | Human neutrophils | 30 | **F, G⁻, G⁺** | [50] |
| 2 | Α Defensins | Human neutrophils | 12-80 | **F, G⁻, G⁺** | [51] |
| 3 | Human Histatin 8 | *Homo sapiens* | 12 | **F, G⁻, G⁺** | [52] |
| 4 | LL37 | Neutrophils (*Homo sapiens*) | 37 | **F, G⁻, G⁺** | [53] |

| From Animals | **Source** | **Amino Acid Number** | **Antimicrobial Activity** | **References** |
|-------------|-----------|-----------------------|-----------------------------|------------|
| 1 | Androctonin | *Androctonus australis* | 25 | **F, G⁻, G⁺** | [54] |
| 2 | Bactenecin | Bovine Neutrophils | 12 | **G⁻, G⁺** | [55] |
| 3 | Brevinin | *Rana brevipora porsa* | 24 | **G⁻, G⁺** | [56] |
| 4 | Buforin II | *Bufo bufo gargarizans* | 21 | **F, G⁻, G⁺** | [57] |
| 5 | CUPIennin | *Cupiennius salei* | 35 | **G⁻, G⁺** | [58] |
| 6 | Dermaseptin S1 | *Phylomedusa sauavagii* | 34 | **G⁻, G⁺** | [59] |
| 7 | Lycotoxin | *Lycosa carolinensis* | 27 | **G⁻, G⁺** | [60] |
| 8 | Tachyplesins | *Tachypleus tridentatus* (Horseshoe crab) | 17 | **G⁻** | [61] |

| From Plants | **Source** | **Amino Acid Number** | **Antimicrobial Activity** | **References** |
|-------------|-----------|-----------------------|-----------------------------|------------|
| 1 | Hevein | Latex of rubber trees | 43 | **F** | [62] |
| 2 | Purothionins | Wheat endosperm | 45 | **G⁻, G⁺** | [63] |

| From Microorganisms | **Source** | **Amino Acid Number** | **Antimicrobial Activity** | **References** |
|---------------------|-----------|-----------------------|-----------------------------|------------|
| 1 | Nisin | *Lactococcus lactis* | 34 | **G⁻** | [64] |
| 2 | Alamethicin | *Trichoderma viride* | 20 | **G⁺** | [65] |
| 3 | Enterocin | *Enterococcus* | 70 | **G⁻, G⁺** | [66] |
| 4 | Hominicin | *Staphylococcus hominis MBBL 2-9* | 21 | **G⁻, G⁺** | [67] |
| 5 | Ericin S | *Bacillus subtilis* | 32 | **G⁺** | [68] |
| 6 | Plantaricin A | *Lactobacillus plantarum* | 26 | **G⁻, G⁺** | [69] |
| 7 | Carnobacteriocin B2 | *Carnobacterium piscicola* | 48 | **G⁻, G⁺** | [70] |

Table 1 contd....
## Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications

**Protein & Peptide Letters, 2020, Vol. 27, No. 1**

| S. No. | Peptide Name            | Source                                | Amino Acid Number | Antimicrobial Activity | References |
|--------|-------------------------|---------------------------------------|-------------------|------------------------|------------|
| 8      | Leucocin A              | *Leuconostoc pseudomesenteroides*     | 37                | G⁺, G⁻                 | [71]       |
| 9      | Subtilin                | *Bacillus subtilis*                   | 32                | G⁻                     | [72]       |
| 10     | Pyrularia thionin       | *Pyrularia pubera*                    | 47                | G⁺, G⁻                 | [73]       |
| 11     | Microcin J25            | *Escherichia coli AY25*               | 21                | G⁻                     | [74]       |
| 12     | Gramicidin A            | *Bacillus brevis*                     | 15                | G⁺, G⁻                 | [75]       |
| 13     | Pediocin PA-1/ AcH      | *Pediococcus acidilactici PAC-1.0*   | 44                | G⁻                     | [76]       |
| 14     | Mesentericin Y105       | *Leuconostoc mesenteroides*           | 37                | G⁻                     | [77]       |
| 15     | Carnobacteriocin BM1    | *Carnobacterium piscicola LV17B*      | 43                | G⁺, G⁻                 | [78]       |
| 16     | Streptin 1              | *Bacillus subtilis A1/3*              | 23                | G⁻                     | [79]       |
| 17     | Planosporicin           | *Planomonospora alba*                 | 24                | G⁺, G⁻                 | [80]       |
| 18     | Gassericin A            | *Lactobacillus gasseri LA39*          | 58                | G⁺, G⁻                 | [81]       |
| 19     | Circularin A            | *Clostridium beijerinckii ATCC 25752*| 69                | G⁺, G⁻                 | [82]       |
| 20     | Divercin V41            | *Carnobacterium divergens V41*        | 43                | G⁻                     | [83]       |
| 21     | Listeriocin 743A        | *Listeria innocua 743*                | 43                | G⁺                     | [84]       |
| 22     | Plantaricin C19         | *Lactobacillus plantarum C19*         | 37                | G⁻                     | [85]       |
| 23     | Enterocin P             | *Enterococcus faecium P13*            | 44                | G⁻                     | [86]       |
| 24     | Subtilosin A            | *Bacillus subtilis*                   | 35                | G⁺, G⁻                 | [87]       |
| 25     | Plantaricin ASM1        | *Lactobacillus plantarum A-1*         | 43                | G⁻                     | [85]       |
| 26     | Lichenin                | *Bacillus licheniformis*              | 12                | G⁺, G⁻                 | [88]       |

F – Fungus; G⁺ - Gram positive; G⁻ - Gram negative.

**Figure 1.** Various models demonstrating mechanism of action of AMPs.
Table 2. Antimicrobial peptide displaying intracellular membrane activities.

| S. No. | AMPs                                      | Intracellular Target                  | References |
|--------|-------------------------------------------|---------------------------------------|------------|
| 1      | Buforin II, tachyplesin                    | Binds to DNA                          | [118]      |
| 2      | Pleurocidin, dermaseptin, PR-39, HNP-1, HNP-2, Indolicidin | Inhibits DNA, RNA and protein synthesis | [119]      |
| 3      | Histatins, pyrrhocoricin, Drosocin, Apidaecin | Inhibits enzymatic activity            | [18]       |
| 4      | N-acetylmuramoyl-L-alanine Amidase          | Activation of autolysin                | [120]      |
| 5      | PR-39, PR-26, indolicidin, microcin 25     | Alters cytoplasmic membrane (inhibits septum formation) | [121]      |
| 6      | Mersacidin                                 | Inhibits cell-wall Synthesis           | [100]      |

Table 3. Inhibitory activity of antimicrobial peptides and proteins against relevant pathogens in ocular infections.

| Protein/Peptide | Microorganisms                          | References |
|-----------------|-----------------------------------------|------------|
| HB43, HB55, HBPMM4 | Staphylococcus aureus               | [130]      |
| HBCM2, HBCM3, HB14 | Pseudomonas aeruginosa             | [131]      |
| Lactoferrin     | Haemophilus influenzae, Staphylococcus, epidermidis, Pseudomonas spp. | [132]      |
| Lactoferricin B | Aspergillus fumigatus, Candida albicans | [14]       |
| Mucins          | Candida spp., P. aeruginosa            | [43, 133]  |
| NP-1            | C. albicans, Streptococcus pneumoniae, P. aeruginosa | [134]      |
| Protegrin-1     | S. aureus, P. aeruginosa              | [135]      |
| Shiva-11        | S. aureus, S. pneumoniae, P. aeruginosa | [136]      |
| Thiazomycin A   | S. aureus                              | [115]      |
| COL-1           | Pseudomonas                            | [137]      |

Injectable preparation of rBPI21 used in treatment of paediatric patients undergoing open heart surgery and patients with severe burns [124]. A recombinant peptide HBD-2 is being used in eliminating the infections attained during the use of prosthetics implantation [125]. Peptides derived from amphibian skin e.g. alyteserin, brevinin, ascaphin, pseudin, kassinatuerin and temporin have been effectively used in the treatment of local infections caused by multi-drug resistant strains of bacteria e.g. Acinetobacter baumannii strains, Klebsiella pneumoniae, Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida sp. [126]. P113 is another peptide naturally occurring in saliva [10], which display high in vitro activity against Candida albicans and commonly occurring Gram-positive and Gram-negative pathogens, it is also being used in the form of a mouthwash for the treatment of oral Candidiasis in HIV patients [127]. Pexiganan is first antimicrobial peptide used in the form of an ointment for treating local infection encountered during diabetic foot ulcers [128]. Variants of indolicidin-based peptide, MX-226 and MX-594AN (omiganan pentahydrochloride, 1% gel) are being used in treating infections associated with the use of catheters and against treatment of Acne vulgaris respectively [129]. Another peptide MBI-853NL is being used in preventing infection associated with Methicillin-Resistant Strains (MRSA), it also eliminates their carriage to nasal cavity [122]. IB-367 is a variant of porcine protegrin-1 which is used in treatment of oral mucositis, a side-effect of anticancer therapies with ‘mixed’ infections in the mouth.

5. AMPs IN CLINICAL TRIALS

Due to numerous advantages of antimicrobial peptides such as high potency, efficacy selectivity, broad range targets, potentially low toxicity and low accumulation in tissues, pharmaceutical industries aims to develop them as therapeutic drugs and appropriate clinical trials therefore are
Table 4. Peptide antibiotics in clinical trials.

| Peptide          | Company             | Clinical Trial Phase | Spectrum/Mode of Action                                                                                     | References |
|------------------|---------------------|----------------------|-------------------------------------------------------------------------------------------------------------|------------|
| CZEN-002         | Zengen              | Phase I/II           | GPB, GNP, Candida. Yeast regulatory mechanisms, Interference by cAMP induction, anti-inflammatory.         | [155]      |
| Daptomycin       | Cubicin             | In market            | GPB. Depolarisation of membrane potential, inhibition of protein, DNA and RNA synthesis.                   | [156]      |
| EA-230           | Exponential biotherapies | Phase I/II       | Anti-inflammatory. Sepsis and renal failure protection.                                                  | [157]      |
| Pexiganan (MSI-78)| Genaera Corporation| Phase III            | Infected diabetic foot ulcers                                                                          | [158]      |
| Omiganan         | MGENIX              | Phase II/III         | Catheter infections and rosacea                                                                         | [159, 160]|
| Lytxar (LTX-109) | Lytix Biopharma     | Phase I/II           | Uncomplicated Gram positive skin infections, impetigo, and nasal colonization with S. aureus             | [130]      |
| hlF1-11          | AM-Pharma           | Phase I/II           | Bacteraemia and fungal infections in immunocompromized haematopoetic stem cell transplant recipients     | [161]      |
| Novexatin (NP-213)| NovaBiotics        | Phase II             | Onychomycosis (fungal nail infection)                                                                    | [162]      |
| LL-37            | Karolinska Institute| Phase I/II           | Hard-to-heal venous leg ulcers                                                                          | [163]      |
| PAC-113          | Demegen             | Phase II             | Oral candidiasis in HIV seropositive patients                                                           | [130]      |
| RDP-58           | Genzyme             | Post Phase II        | Inflammatory bowel disease                                                                               | [164]      |
| MX-594AN         | Migenix             | Phase II             | Topical treatment for Acne vulgatis                                                                      | [165]      |
| MX-226           | Migenix             | Phase III b          | Dermatology related infections                                                                           | [153]      |
| HB-1345          | BioMedix            | Pre-Phase I          | Acne                                                                                                      | [166]      |
| HB-107           | Biopharmaceuticals  | Preclinical          | Wound healing                                                                                             | [167]      |
| Glutoxim         | Pharma BAM          | Phase II             | Tuberculosis                                                                                              | [168]      |
| IMX942           | Inimex              | Phase I A            | Immunomodulation, Treatment of fevers in chemotherapy patients                                          | [158]      |
| DPK-060          | Promore Pharma      | Phase II             | Treatment of atopic dermatitis                                                                           | [169]      |
| POL7080          | Polyphor Ltd        | Phase II             | Treatment of non-cystic fibrosis bronchiectasis                                                          | [170]      |
| SB006            | SpiderBiotech (Italy)| Preclinical        | Antiendotoxic activity                                                                                   | [171]      |
| PL-5             | China Food and Drug Administration (CFDA) | Phase II | Treatment of skin infections                                                                             | [172]      |

being conducted [138]. More than 60 peptide drugs have reached the market and several hundred novel therapeutic peptides are in preclinical and clinical development [139] (Table 4). Emerging peptide technologies, including multifunctional peptides, cell penetrating peptides and peptide drug conjugates will widen the application of peptides as therapeutics [140]. United States of America dominates the global production and commercialization of peptide drug followed by Europe. Companies like Theravance and Vicuron Pharmaceuticals are the major American companies largely dedicated in the development of peptide antibiotics [141]. However, certain peptides could not have entered clinical trials, MSI-78 (pexiganan acetate, which is a potent antimicrobial peptide designed from Magainin) was a prominent failure that has entered phase III of clinical trials and showed efficacy against diabetic foot ulcer infections [43], however, in July 1999, the FDA disapproved use of Magainin based on inadequacy trial design. Iseganan IB-367, a synthetic protegrin analogue failed Phase III clinical trials as mouth rinse for stomatitis in
high risk patients owing to aerosolized Rx in ventilator-associated pneumonia [142]. The trial achieved its secondary endpoint for reduction of pain but did not meet the primary end point for presence of ulceration. Nevertheless, this trial continues to enroll patients for a second phase III trial [143]. Micrologix Biotech Inc. has introduced 3 separate antimicrobial peptides related to indolicidin into clinical trials [144]. The most advanced peptide MBI-226 [115] has entered phase III clinical trials for preventing catheter-related bloodstream infections. According to company press releases and conference presentations, preclinical studies demonstrated that MBI-226 is effective in animal models, it has successfully reduced the skin colonization by variety of bacteria causing catheter-related infections [145], and also demonstrated good antifungal activity against Candida albicans in guinea pig skin [146]. A randomized, double-blind phase I clinical trial in 18 healthy volunteers demonstrated that MBI-226 was safe, well tolerated and eliminated 99.9% of common skin bacteria for prolonged periods [147]. Furthermore, it completely prevented short-term Central Venous Catheter (CVC) colonization Since CVC colonization is a common cause of serious life-threatening infections in hospitalized patients, causing 90% (180,000/year) of bloodstream infections that results in an average of 6.5 additional days of intensive care and up to 50,000 deaths annually [148]. Micrologix received fast track status from the FDA and initiated two clinical trials using indolicidin-like peptides for treatment of acute acne (in phaseII clinical trials) and killing MRSA in the nares (in phase Ib trials) [149, 150].

All over, use of AMPs have proven to be successful in treating infections, in fact, antimicrobial peptide have already entered the global market e.g. magainin is being used in treating viral and bacterial diseases [151, 152]. Several studies carried out globally by researchers have provided in depth understanding about antimicrobial peptides mechanism, efficacy, safety, and other related concern and has helped in creating online database service as well as the future potential of AMPs [22, 153, 154]. Incontestable need for new ways to manage infections and the proven importance of peptides in innate immunity should render the investment worthwhile for human medicine. The research investments are needed to bring more peptide antibiotics to the clinic will likely remain substantial in the foreseeable future. As described below, a number of AMPs and AMP derivatives are already at the pre-clinical stage and in clinical trials.

CONCLUSION

Antimicrobial resistance is multifaceted, multi-dimensional, and is second largest cause of deaths in the world. Both the Gram positive and Gram negative bacteria are getting refractory to current armamentarium of antimicrobial drugs. Treatment of bacterial infections caused by MDR strains that include vancomycin-resistant Enterococcus faecium, Enterobacter cloacae (MRSA), XDR strains that include carbapenem-resistant Acinetobacter baumannii, and third generation cephalosporin resistant E. coli, β-lactamase producing Klebsiella pneumonia, carbapenem-resistant Klebsiella pneumoniae, carbapenem-resistant Pseudomonas aeruginosa and Mycobacterium has become quite difficult. All living organisms are constantly threatened by large numbers of microorganisms seeking to exploit the same environmental space. To cope with this substantial microbial threat, most cells produce natural antibiotic like molecules that directly kill or inhibit the growth of foreign microorganisms. The urgent need to obtain new antimicrobials has been driving AMP research. In this respect, AMPs are considered as promising antimicrobial agents for producing new generation antimicrobials. Although there are several obstacles to be overcome for clinical applications, natural and synthetic AMPs are still attractive sources to the pharmaceutical companies. In order to facilitate commercial development of peptide antibiotics, it is reasonable to focus on small peptides.

LIST OF ABBREVIATIONS

AMPS = Antimicrobial Peptides
E. coli = Escherichia coli
APD = Antimicrobial Peptide Database
sp. = Species
prAMPs = proline rich Antimicrobial Peptides
F = Fungus
G+ = Gram positive
G- = Gram negative
DNA = Deoxyribonucleic Acid
RNA = Ribonucleic Acid
e.g. = exempli gratia
HIV = Human Immunodeficiency Virus
MRSA = Methicillin-Resistant Staphylococcus aureus
P. aeruginosa = Pseudomonas aeruginosa
C. albicans = Candida albicans
S. aureus = Staphylococcus aureus
S. pneumonia = Streptococcus pneumoniae
FDA = Food and Drug Administration
CVC = Central Venous Catheter
cAMP = Cyclic Antimicrobial peptides
MDR = Multidrug-Resistant
XDR = Extensive Drug Resistant

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.
of antimicrobial peptides from fish isolate *Carnobacterium maltaromaticum* C2: Carnobacteriocin X and camolysins A1 and A2. *Int. J. Food Microbiol.*, 2014, 173, 81-88. [http://dx.doi.org/10.1016/j.ijfoodmicro.2013.12.019] [PMID: 24412962]

[79] Bosma, T.U.S. Bacterial surface display and screening of thioredoxin-bridging containing peptides. *U.S. Patent No. 9,651,558, 2017.*

[80] Gajalakshmi, P. Selective isolation and characterization of rare actinomycetes adopted in glacier soil of Manali ice point and its activity against *Mycobacterium spp*. *J. Microbiol. Biotechnol. Res.*, 2017, 7(5), 1-10. [http://dx.doi.org/10.24986/jmbr.2017751]

[81] Maldonado-Barragán, A.; Caballero-Guerrero, B.; Martín, V.; Ruiz-Barba, J.L.; Rodríguez, J.M. Purification and genetic characterization of gassericin E, a novel co-culture inducible bacteriocin from *Lactobacillus gasseri* EV1461 isolated from the vagina of a healthy woman. *BMC Microbiol.*, 2016, 16(1), 37. [https://doi.org/10.1186/s12866-016-0666-3] [PMID: 26960428]

[82] Perez, R.H.; Ishibashi, N.; Inoue, T.; Himeno, K.; Masuda, Y.; Sawa, N. Functional analysis of genes involved in the biosynthesis of enterocin NKR-5-3B, a novel circular bacteriocin. *J. Bacteriol.*, 2016, 198(2), 291-300. [https://doi.org/10.1128/JB.00692-15]

[83] Brillet-Viel, A.; Filet, M.F.; Couroux, P.; Prévost, H.; Leroi, F. Optimization of growth and bacteriocin activity of the food bioprotective *Carnobacterium diversogenes* V41 in an animal origin protein free medium. *Front. Mar. Sci.*, 2016, 3, 128. [http://dx.doi.org/10.3389/fmars.2016.00128]

[84] Wan, X.; Li, R.; Saris, P.E.; Takala, T.M. Genetic characterisation and heterologous expression of leucocin C, a class IIa bacteriocin from *Leuconostoc carnosum* 4010. *Appl. Microbiol. Biotechnol.*, 2013, 97(8), 3509-3518. [http://dx.doi.org/10.1007/s00253-012-4406-4] [PMID: 23053700]

[85] Wang, Y.; Yang, N.; Qin, Y.; Zhang, Y.; Zhang, J.; Li, P. The complete genome sequence of *Lactobacillus plantarum* LPL-1, a novel bacteriophage producing class IIa bacteriocin. *J. Biotechnol.*, 2018, 266, 84-88. [http://dx.doi.org/10.1016/j.jbiotec.2017.12.006] [PMID: 29229543]

[86] Le, T.N.; Do, T.H.; Nguyen, T.N.; Tran, N.T.; Ensors, S.O.; Truong, H. Expression and simple purification strategy for the generation of anti-microbial active Enterocin P from *Enterococcus faecium* expressed in *Escherichia coli* ER2566. *Iranian J. Biotechnol.*, 2014, 12(4), 17-25. [http://dx.doi.org/10.15171/jib.1154]

[87] Venturina, D.H.; Villegas, L.C.; Perez, M.T.M.; Elegado, F.B. Identification and isolation of subtilisin A-producing *Bacillus subtilis* from mango sprouts, silage and soil samples in the Philippines. *Asia Life Sci.*, 2016, 25(1), 123-136.

[88] Gavito-Hernández, A.; Vázquez-Domínguez, G.; Rueda-Céspedes, M. Optimization of growth and bacteriocin production of the food bioprotective *Lactobacillus plantarum* EV1461 isolated from the vagina of a healthy woman. *Appl. Microbiol. Biotechnol.*, 2017, 101(7), 2719-2734. [http://dx.doi.org/10.1007/s00253-016-7701-x] [PMID: 28373820]

[89] Sun, D.; Forsman, J.; Woodward, C.E. Molecular simulations of melittin-induced membrane pores. *Front. Phys. Chem.*, 2017, 74(4), 663-682. [http://dx.doi.org/10.3389/fchem.2018.00281] [PMID: 29643807]

[90] Pfalzgraff, A.; Brandenburg, K.; Weindl, G. Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. *Front. Pharmacol.*, 2018, 9, 281. [http://dx.doi.org/10.3389/fphar.2018.00218] [PMID: 29643807]

[91] Shafee, T.M.; Lay, F.T.; Phan, T.K.; Anderson, M.A.; Hulett, M.D. Convergent evolution of defensin sequence, structure and function. *Drug Targets Today*, 2002, 2(1), 79-83. [http://dx.doi.org/10.1017/S1479664702150158] [PMID: 12642155]

[92] Shafee, T.M.; Lay, F.T.; Phan, T.K.; Anderson, M.A.; Hulett, M.D. Convergent evolution of defensin sequence, structure and function. *Drug Targets Today*, 2002, 2(1), 79-83. [http://dx.doi.org/10.1017/S1479664702150158] [PMID: 12642155]

[93] Shafee, T.M.; Lay, F.T.; Phan, T.K.; Anderson, M.A.; Hulett, M.D. Convergent evolution of defensin sequence, structure and function. *Drug Targets Today*, 2002, 2(1), 79-83. [http://dx.doi.org/10.1017/S1479664702150158] [PMID: 12642155]
antimicrobial peptides PGLa and magainin 2 in membranes. *Biophys. J.*, 2018, 114(3), 452a–453a.

[https://doi.org/10.1016/j.bpj.2017.11.2502](https://doi.org/10.1016/j.bpj.2017.11.2502)

[95] Xhindi, D.; Pucor, S.; Benincasa, M.; Scoeci, M.; Gennaro, R.; Tossi, A. The human cathelicidin LL-37–A pore-forming antimicrobial peptide and host-cell modulator. *Biochim. Biophys. Acta.*, 2016, 1858(3), 546–556.

[https://doi.org/10.1016/j.bbamem.2015.11.003] [PMID: 26556394]

[96] Belmadani, A.; Semlali, A.; Rouabhia, M. Dermaseptin and low toxicity on gingival fibroblasts. *Arch. Oral Biol.*, 2016, 70, 79-87.

[https://doi.org/10.1016/j.archoralbio.2016.06.008] [PMID: 27344590]

[97] Tsai, C.W.; Lin, Z.W.; Chang, W.F.; Chen, Y.F.; Hu, W.W. Development of an indolocidin-derived peptide by reducing membrane perturbation to decrease cytoxicity and maintain gene delivery ability. *Colloids Surf B Biointerfaces*, 2018, 165, 18-27.

[https://doi.org/10.1016/j.colsurfb.2018.02.007] [PMID: 29448216]

[98] Zhang, M.; Wei, W.; Sun, Y.; Jiang, X.; Ying, X.; Tao, R.; Ni, L. Pleurocidin congeners demonstrate activity against Streplococcus and low toxicity on gingival fibrobasts. *Arch. Oral Biol.*, 2016, 70, 79-87.

[https://doi.org/10.1016/j.archoralbio.2016.06.008] [PMID: 27344590]

[99] Baindara, P.; Kapoor, A.; Korpole, S.; Grover, V. Membrane-active antimicrobial peptides as template delivery ability. *Biochim. Biophys. Acta.*, 2019, 1865(1), 72-83.

[https://doi.org/10.1016/j.snb.2018.12.007] [PMID: 29448216]

[100] Wuerth, K. Combating *Pseudomonas aeruginosa* lung infections using synthetic host defense peptides. Doctoral dissertation: University of British Columbia, 2017.

[101] Baidara, P.; Kapoor, A.; Korpole, S.; Grover, V. Cysteine-rich low molecular weight antimicrobial peptides from *Brevibacillus* and related genera for biotechnological applications. *World J. Microbiol. Biotechnol.*, 2017, 33(6), 124.

[https://doi.org/10.1007/s11274-017-2291-9] [PMID: 28534113]

[102] Lohner, K. Membrane-active antimicrobial peptides as template structures for novel antibiotic agents. *Curr. Top. Med. Chem.*, 2017, 17(5), 508-519.

[https://doi.org/10.2174/1568026616666160713122404] [PMID: 28117020]

[103] Sani, M.A.; Separovic, F. How membrane-active peptides get into lipid membranes. *Acc. Chem. Res.*, 2016, 49(6), 1130-1138.

[https://doi.org/10.1021/acs.accounts.6b00074] [PMID: 27187572]

[104] Haney, E.F.; Mansour, S.C.; Hancock, R.E. Antimicrobial peptides: an introduction. *Antimicrobial Peptides*: Humana Press: New York, NY, 2017, pp. 3-22.

[105] Mingot-Leclercq, M.P.; Décourt, J.L. Bacterial lipid membranes as promising targets to fight antimicrobial resistance, molecular foundations and illustration through the renewal of aminoglycoside antibiotics and emergence of amphiphilic aminoglycosides. *MedChemComm.*, 2016, 7(4), 586-611.

[https://doi.org/10.1039/CSDM00050E] [PMID: 27187572]

[106] Cudic, M.; Otvos, L.Jr. Intracellular targets of antibacterial peptides. *Curr. Drug Targets.*, 2002, 3(2), 101-106.

[https://doi.org/10.2174/1389450200605445] [PMID: 11958294]

[107] Krizsan, A.; Volke, D.; Heinert, S.; Strätter, N.; Knappe, D.; Hoffmann, R. Insect-derived proline-rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S ribosome. *Angew. Chem. Int. Ed. Engl.*, 2014, 53(45), 12236-12239.

[https://doi.org/10.1002/anie.201407145] [PMID: 25220491]

[108] Mansour, S.C.; Pena, O.M.; Hancock, R.E. Host defense peptides: frontline immunomodulators. *Trends Immunol.*, 2014, 35(9), 443-450.

[https://doi.org/10.1016/j.ti.2014.07.004] [PMID: 25113635]

[109] Clar, B.; Bastos, M.; Garcia-Fandino, R. Design and applications of cyclic peptides. In: *Peptide Applications in Biomedicine, Biotechnology and Bioengineering*. Koutsopoulos S. Ed.; Woodhead Publishing: Sawston, United Kingdom, 2018, pp. 87-129.

[https://doi.org/10.1016/j.ijbiomac.2016.05.023] [PMID: 25113635]

[110] Malanovic, N.; Lohner, K. Antimicrobial peptides targeting gram-positive bacteria. *Pharmaceuticals (Basel)*, 2016, 9(3), 59.

[http://dx.doi.org/10.3390/p7030059] [PMID: 27657092]

[111] Shagaghi, N.; Palombo, E.A.; Clayton, A.H.A.; Blave, M. Antimicrobial peptides: biochemical determinants of activity and biophysical techniques of elucidating their functionality. *World J. Microbiol. Biotechnol.*, 2018, 34(4), 62.

[http://dx.doi.org/10.1127/1874-0142-2017-0265] [PMID: 29651655]

[112] Matsuzaki, K. Why and how are peptide-lipid interactions utilized for self-defense? Magainins and tachyplesins as archetypes. *Biochim. Biophys. Acta.*, 1999, 1462(1–2), 1-10.

[http://dx.doi.org/10.1016/S0006-376X(99)90197-2] [PMID: 10590299]

[113] Han, J.; Zhao, S.; Ma, Z.; Gao, L.; Liu, H.; Muhammad, U. The antibacterial activity and modes of Li-F type antimicrobial peptides against *Bacillus cereus* in vitro. *J. Appl. Microbiol.*, 2017, 123(3), 602-614.

[https://doi.org/10.1111/jam.13526]

[114] Jose, F.; Bobone, S.; Roversi, D.; Mangoni, M.L.; Stella, L. From liposomes to cells: Filling the gap between physicochemical and microbiological studies of the activity and selectivity of host-defence peptides. *Sci. Pharm.*, 2018, 76(5), e24041.

[http://dx.doi.org/10.1002/sep.24041]

[115] Brabu, U.; All, S.; Magray, A.R.; Gunai, B.A.; Firdous, P.; Hassan, T.; Nazir, R. Fish antimicrobial peptides (AMPs) as essential and promising molecular therapeutic agents: A review. *Microb. Pathog.*, 2018, 114, 50-56.

[https://doi.org/10.1016/j.micpath.2017.11.039] [PMID: 29180291]

[116] Malanovic, N.; Lohner, K. Antimicrobial peptides targeting gram-positive bacteria. *Pharmaceuticals (Basel)*, 2016, 9(3), 59.

[http://dx.doi.org/10.3390/pharmaceuticals6040031] [PMID: 27657092]
Mini Review on Antimicrobial Peptides, Sources, Mechanism and Recent Applications

Protein & Peptide Letters, 2020, Vol. 27, No. 1

[126] Migoń, D.; Neubauer, B.; Kamysz, W. Hydroxylated antimicrobial peptides. *Protein J.*, 2018, 37(1), 2-12.

[127] Yu, K.; Lo, J.C.; Yan, M.; Yang, X.; Brooks, D.E.; Hancock, R.E.; Lange, D.; Kizhakkedathu, J.N. Anti-adhesive antimicrobial peptide coating prevents catheter associated infection in a mouse urinary infection model. *Biomaterials*, 2017, 116, 69-81.

[128] Greber, K.E.; Dawgul, M. Antimicrobial peptides under clinical trials. *Curr. Top. Med. Chem.*, 2017, 17(5), 626-628.

[129] Sachdeva, S. Peptides as ‘Drugs’: the journey so far. *Int. J. Pept. Res. Ther.*, 2017, 23(1), 49-60.

[130] Mohammad, H.; Thangamani, S.; Seleem, M.N. Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections. *Curr. Pharm. Des.*, 2015, 21(16), 2073-2088.

[131] Dawgul, M.; Maciejewsk, M.; Karafiova, A.; Kamysz, W. Antimicrobial peptides as potential tool to fight bacterial biofilm. *Acta Pol. Pharm.*, 2014, 71(1), 39-47.

[132] Tsou, Y.A.; Tung, Y.T.; Wu, T.F.; Chang, G.R.L.; Chen, H.C.; Lin, C.D.; Lai, C.H.; Chen, H.L.; Chen, C.M. Lactoferrin interacts with bacterial biofilm. *Biochem. Cell Biol.*, 2017, 95(3), 394-399.

[133] Samad, T.; Co, J.Y.; Witten, J.; Ribbeck, K. Mucus and mucin signaling. *Biochim. Biophys. Acta*, 2019, 5(3), 1189-1194.

[134] Dalini, E.B.M.; Lee, B.H.; Oh, D.H. Current trends and perspectives of bioactive peptides. *Crit. Rev. Food Sci. Nutr.*, 2018, 58(13), 2273-2284.

[135] Kolar, S.S.N.; Luca, V.; Baidouri, H.; Mannino, G.; McDermott, A.M.; Mangoni, M.L. Esculentin-1a (1-21) NH 2: a frog skin-derived peptide for microbial keratitis. *Cell. Mol. Life Sci.*, 2015, 72(3), 617-627.

[136] Bach, H. A New Era without Antibiotics. *2018, 1.*

[137] Lavoie, D.; Dunn, M.K. Therapeutic peptides: Historical perspectives, current development trends, and future directions. *Bioorg. Med. Chem.*, 2018, 26(10), 2700-2707.

[138] Raucher, D.; Ruy, J.S. Cell-penetrating peptides: strategies for anticancer treatment. *Trends Mol. Med.*, 2015, 21(9), 560-570.

[139] Lango, D.; Kamysz, W. Peptidomimetics: Novel approaches for designing of antimicrobial peptides. *Acta Pol. Pharm.*, 2016, 71(5), 63.

[140] Ben Llagha, A.; Haas, B.; Gottschalk, M.; Gresen, D. Antimicrobial potential of bacteriocins in poultry and swine production. *Vet. Res. (Faisalabad)*, 2017, 48(1), 22.

[141] Gabaratz, K.; Kamysz, W.; Piechowicz, L. Activity of antimicrobial peptides, alone or combined with conventional antibiotics, against *Staphylococcus aureus* isolated from the airways of cystic fibrosis patients. *Virulence*, 2017, 8(1), 94-100.

[142] [http://dx.doi.org/10.1093/jac/dks513] [PMID: 23302580]

[143] [http://dx.doi.org/10.1080/21505594.2016.1213475] [PMID: 27450039]

[144] Hueque, M.; Röhmel, J. Multiplicity problems in clinical trials: a regulatory perspective In: *Multiple testing problems in pharmaceutical statistics*. Breit, F.; Tamhane, A.C., Eds.; CRC Press: USA, 2008, pp. 13-34.

[145] [http://dx.doi.org/10.1217/mm/2016-0057] [PMID: 27348155]

[146] [http://dx.doi.org/10.1016/j bjমে.2016.11.047] [PMID: 28450805]

[147] [http://dx.doi.org/10.1039/c7em00063j] [PMID: 28971093]

[148] [http://dx.doi.org/10.1011/ceji.2016.65141] [PMID: 25760338]

[149] [http://dx.doi.org/10.1080/13543776.2017.1259411] [PMID: 28422728]

[150] [http://dx.doi.org/10.1016/bs.ircmb.2014.12.001] [PMID: 25708465]

[151] [http://dx.doi.org/10.1080/02698892.2012.694249] [PMID: 23744235.18488110]

[152] [http://dx.doi.org/10.1080/13543776.2017.1259411] [PMID: 25708465]

[153] [http://dx.doi.org/10.1002/cmdc.201500299] [PMID: 26386345]

[154] [http://dx.doi.org/10.1080/23744235.2018.1448110] [PMID: 28581672]
[160] Ross, J.E.; Jones, R.N.; Rhomberg, P.R.; Fritsche, T.R. In: *In vitro activity of omiganan pentahydrochloride against > 1,600 clinical trial isolates*, 45th Infectious Diseases Society of America Annual Meeting, San Diego, 2007, 433.

[161] Morici, P.; Fais, R.; Rizzato, C.; Tavanti, A.; Lupetti, A. Inhibition of *Candida albicans* biofilm formation by the synthetic lactoferricin derived peptide hLF1-11. *PLoS One*, 2016, 11(11), e0167470. [http://dx.doi.org/10.1371/journal.pone.0167470] [PMID: 27902776]

[162] Javia, A.; Amrutiya, J.; Lalani, R.; Patel, V.; Bhatt, P.; Misra, A. Antimicrobial peptide delivery: an emerging therapeutic for the treatment of burn and wounds. *Ther. Deliv.*, 2018, 9(5), 375-386. [http://dx.doi.org/10.4155/tde-2017-0061] [PMID: 29681237]

[163] De Lorenzi, E.; Chiari, M.; Colombo, R.; Cretich, M.; Sola, L.; Vanna, R. Evidence that the human innate immune peptide LL-37 may be a binding partner of Abeta and inhibitor of fibril assembly. *Biophys. J.*, 2018, 114(3), 393a. [http://dx.doi.org/10.5152/IstanbulJPharm.2017.0012]

[164] Menko, A.S. Method to treat and prevent posterior capsule opacification. Patent. 8,999,370, 2015.

[165] Moorthy, N.S.H.N.; Pratheepa, V.; Manivannan, E. Natural product derived drugs for immunological and inflammatory diseases. *Nat. Prod. Clin. Trials*, 2018, 1, 1-31.

[166] Döşler, S. Antimicrobial peptides: Coming to the end of antibiotic era, the most promising agents. *Ist. J. Pharm.*, 2017, 47(2), 72-76. [http://dx.doi.org/10.5152/IstanbulJPharm.2017.0012]

[167] Mangoni, M.L.; McDermott, A.M.; Zasloff, M. Antimicrobial peptides and wound healing: biological and therapeutic considerations. *Exp. Dermatol.*, 2016, 25(3), 167-173. [http://dx.doi.org/10.1111/exd.12929] [PMID: 26738772]

[168] Feng, Q.; Huang, Y.; Chen, M.; Li, G.; Chen, Y. Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo. *Eur. J. Clin. Microbiol. Infect. Dis.*, 2015, 34(1), 197-204. [http://dx.doi.org/10.1007/s10096-014-2219-3] [PMID: 25169965]